We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
- Authors
Grinshpun, Albert; Tolaney, Sara M.; Burstein, Harold J.; Jeselsohn, Rinath; Mayer, Erica L.
- Abstract
The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the first-line setting for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Randomized trials have demonstrated similar and significant improvements in progression-free survival using the three available CDK4/6 inhibitors and led to regulatory approval. However, mature overall survival data now suggest potential differences among the various agents, suggesting an evolution in selection preferences.
- Subjects
CYCLIN-dependent kinase inhibitors; METASTATIC breast cancer; DILEMMA; PROGRESSION-free survival; REGULATORY approval
- Publication
NPJ Breast Cancer, 2023, Vol 9, Issue 1, p1
- ISSN
2374-4677
- Publication type
Article
- DOI
10.1038/s41523-023-00520-7